February 3, 2021- Receipt of dedicated CPT® code marks important commercialization milestone to pursue reimbursement for the PreTRM® Test.
January 05, 2021- Patient enrollment began in November for this rigorous prospective, randomized, controlled PRIME intervention trial to demonstrate the value of implementing the PreTRM® prevention strategy to improve neonatal outcomes and lower cost of care.
September 9, 2020- Sera will be presenting at the upcoming Baird 2020 Global Health Care Conference. A virtual conference, Sera’s presentation will take place on Thursday, September 10 at 10:50 a.m. ET.
June 24, 2020 - Sera announced the appointment Thomas J. Garite, M.D. as Vice President of Clinical Sciences. - Dr. Garite will support clinical development and operations as Sera transitions from clinical to commercial-stage company.
May 20, 2020 - Sera Prognostics, Inc., The Pregnancy Company® announced the publication of positive data in a large, independent, contemporary prospective U.S. clinical cohort study, TREETOP (NCT02787213), in the American Journal of Obstetrics & Gynecology Maternal Fetal Medicine.